GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹16 Cr | ₹22 Cr | ₹13 Cr | ₹75 Cr | ₹12 Cr |
What is the latest Contingent Liabilities ratio of GLAND PHARMA ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹16 Cr |
Mar2023 | ₹22 Cr |
Mar2022 | ₹13 Cr |
Mar2021 | ₹75 Cr |
Mar2020 | ₹12 Cr |
How is Contingent Liabilities of GLAND PHARMA Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹16 Cr | -29.41 | |
Mar2023 | ₹22 Cr | 72.94 | |
Mar2022 | ₹13 Cr | -82.91 | |
Mar2021 | ₹75 Cr | 531.25 | |
Mar2020 | ₹12 Cr | - |
Compare Contingent Liabilities of peers of GLAND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLAND PHARMA | ₹27,879.2 Cr | -8.6% | -4.9% | -8.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹418,936.0 Cr | -5.8% | -3.2% | 35.1% | Stock Analytics | |
DIVIS LABORATORIES | ₹152,157.0 Cr | -2.8% | -3.6% | 44.7% | Stock Analytics | |
CIPLA | ₹116,200.0 Cr | -3.9% | -0.5% | 13.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹111,325.0 Cr | -1.2% | 7.1% | 17.8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹98,037.4 Cr | -2.7% | -0.1% | 40.9% | Stock Analytics |
GLAND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLAND PHARMA | -8.6% |
-4.9% |
-8.1% |
SENSEX | -2.1% |
-6.4% |
7% |
You may also like the below Video Courses